That's actually pretty good.
They have been able to offset their outgoings by about 15% with their ongoing sales.
In addition, the sought R&D refund for the 2nd qtr should mean they should be in front.
Wow, a biotech that doesn't burn cash!
This SP is phenomenally undervalued in my opinion.
